Clinical Trial Update: Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

View source ↗

Summary

Named patient use program for abemaciclib to treat metastatic breast cancer has been approved for marketing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Abemaciclib (Verzenio) (abemaciclib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Metastatic Breast Cancer | Status: APPROVED_FOR_MARKETING